StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$61.43+2.92 (+4.99%)

Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –

BioMarin Pharmaceutical pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

BioMarin Pharmaceutical's pe ratio was 153.5× on Nov 11, 2026, against 21.1× a year earlier. Over the last 5 years it ranged from 15.9× to 478.1×, with a median of 76.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026153.5×+131.1
2025Dec 31, 202522.4×−16.9
2024Dec 31, 202439.4×−85.9
2023Dec 29, 2023125.2×−121.2
2022Dec 30, 2022246.4×+227.8
2021Oct 29, 202118.6×−1.5
2020Dec 31, 202020.1×−3.0
2011Oct 31, 201123.0×+7.5
2010Dec 31, 201015.6×−49.3
2009Dec 31, 200964.9×–

More BioMarin Pharmaceutical figures

See a number that looks wrong?